{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:19:03Z","timestamp":1783937943284,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00395-019-0733-2","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T03:02:33Z","timestamp":1555642953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Inhibition of sodium\u2013glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization"],"prefix":"10.1007","volume":"114","author":[{"given":"Hana E.","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Kiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"Luebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake R.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner C.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Roell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan D.","family":"Tune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam G.","family":"Goodwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"733_CR1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12881","volume":"19","author":"H Al Jobori","year":"2017","unstructured":"Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo RA, Abdul-Ghani M (2017) Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab 19:809\u2013813. \nhttps:\/\/doi.org\/10.1111\/dom.12881","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 5","key":"733_CR2","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1097\/00005344-199206205-00007","volume":"20","author":"I Amende","year":"1992","unstructured":"Amende I, Bentivegna L, Morgan JP (1992) Ventricular function and calcium handling during ischemia. J Cardiovasc Pharmacol 20(Suppl 5):S42. \nhttps:\/\/doi.org\/10.1097\/00005344-199206205-00007","journal-title":"J Cardiovasc Pharmacol"},{"key":"733_CR3","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou PE, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, Brizzi MF, Dimitriadis G, Iliodromitis EK (2017) Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 8:1077. \nhttps:\/\/doi.org\/10.3389\/fphys.2017.01077","journal-title":"Front Physiol"},{"key":"733_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia 60:568\u2013573. \nhttps:\/\/doi.org\/10.1007\/s00125-016-4134-x","journal-title":"Diabetologia"},{"key":"733_CR5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jacc.2012.08.1021","volume":"61","author":"M Bayeva","year":"2013","unstructured":"Bayeva M, Gheorghiade M, Ardehali H (2013) Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 61:599\u2013610. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2012.08.1021","journal-title":"J Am Coll Cardiol"},{"key":"733_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","volume":"2","author":"NJ Byrne","year":"2017","unstructured":"Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, Fedak PWM, Verma S, Dyck JRB (2017) Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci 2:347\u2013354. \nhttps:\/\/doi.org\/10.1016\/j.jacbts.2017.07.003","journal-title":"JACC Basic Transl Sci"},{"key":"733_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","volume":"1","author":"J Chen","year":"2010","unstructured":"Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, Feder JN (2010) Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 1:57\u201392. \nhttps:\/\/doi.org\/10.1007\/s13300-010-0006-4","journal-title":"Diabetes Ther"},{"key":"733_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","volume":"13","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28. \nhttps:\/\/doi.org\/10.1186\/1475-2840-13-28","journal-title":"Cardiovasc Diabetol"},{"key":"733_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/dom.12572","volume":"17","author":"R Chilton","year":"2015","unstructured":"Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17:1180\u20131193. \nhttps:\/\/doi.org\/10.1111\/dom.12572","journal-title":"Diabetes Obes Metab"},{"key":"733_CR10","first-page":"82S","volume":"13","author":"MS Chow","year":"1993","unstructured":"Chow MS (1993) Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors. Pharmacotherapy 13:82S\u201387S","journal-title":"Pharmacotherapy"},{"key":"733_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/jcph.88","volume":"53","author":"D Devineni","year":"2013","unstructured":"Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53:601\u2013610. \nhttps:\/\/doi.org\/10.1002\/jcph.88","journal-title":"J Clin Pharmacol"},{"key":"733_CR12","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40262-015-0285-z","volume":"54","author":"D Devineni","year":"2015","unstructured":"Devineni D, Polidori D (2015) Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium\u2013glucose co-transporter 2 inhibitor. Clin Pharmacokinet 54:1027\u20131041. \nhttps:\/\/doi.org\/10.1007\/s40262-015-0285-z","journal-title":"Clin Pharmacokinet"},{"key":"733_CR13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/0022-2828(90)91474-L","volume":"22","author":"EO Feigl","year":"1990","unstructured":"Feigl EO, Neat GW, Huang AH (1990) Interrelations between coronary artery pressure, myocardial metabolism and coronary blood flow. J Mol Cell Cardiol 22:375\u2013390","journal-title":"J Mol Cell Cardiol"},{"key":"733_CR14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a \"Thrifty Substrate\" hypothesis. Diabetes Care 39:1108\u20131114. \nhttps:\/\/doi.org\/10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"733_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, Broedl UC, Woerle HJ (2014) Metabolic response to sodium\u2013glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Investig 124:499\u2013508. \nhttps:\/\/doi.org\/10.1172\/JCI72227","journal-title":"J Clin Investig"},{"key":"733_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/iub.1253","volume":"66","author":"N Fillmore","year":"2014","unstructured":"Fillmore N, Lopaschuk GD (2014) Malonyl CoA: a promising target for the treatment of cardiac disease. IUBMB Life 66:139\u2013146. \nhttps:\/\/doi.org\/10.1002\/iub.1253","journal-title":"IUBMB Life"},{"key":"733_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/cvr\/21.7.537","volume":"21","author":"D Garcia-Dorado","year":"1987","unstructured":"Garcia-Dorado D, Theroux P, Elizaga J, Galinanes M, Solares J, Riesgo M, Gomez MJ, Garcia-Dorado A, Fernandez Aviles F (1987) Myocardial reperfusion in the pig heart model: infarct size and duration of coronary occlusion. Cardiovasc Res 21:537\u2013544","journal-title":"Cardiovasc Res"},{"key":"733_CR18","doi-asserted-by":"publisher","first-page":"H478","DOI":"10.1152\/ajpheart.00749.2016","volume":"312","author":"S Gent","year":"2017","unstructured":"Gent S, Skyschally A, Kleinbongard P, Heusch G (2017) lschemic preconditioning in pigs: a causal role for signal transducer and activator of transcription 3. Am J Physiol Heart Circ Physiol 312:H478\u2013H484. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00749.2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"733_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cmet.2015.01.005","volume":"21","author":"PA Gorski","year":"2015","unstructured":"Gorski PA, Ceholski DK, Hajjar RJ (2015) Altered myocardial calcium cycling and energetics in heart failure\u2014a rational approach for disease treatment. Cell Metab 21:183\u2013194. \nhttps:\/\/doi.org\/10.1016\/j.cmet.2015.01.005","journal-title":"Cell Metab"},{"key":"733_CR20","doi-asserted-by":"publisher","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","volume":"309","author":"Y Han","year":"2015","unstructured":"Han Y, Cho YE, Ayon R, Guo R, Youssef KD, Pan M, Dai A, Yuan JX, Makino A (2015) SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol 309:L1027\u20131036. \nhttps:\/\/doi.org\/10.1152\/ajplung.00167.2015","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"733_CR21","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1113\/jphysiol.1995.sp020559","volume":"482","author":"MA Hediger","year":"1995","unstructured":"Hediger MA, Kanai Y, You G, Nussberger S (1995) Mammalian ion-coupled solute transporters. J Physiol 482:7S\u201317S. \nhttps:\/\/doi.org\/10.1113\/jphysiol.1995.sp020559","journal-title":"J Physiol"},{"key":"733_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752\u2013772. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021887","journal-title":"Circulation"},{"key":"733_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.yjmcc.2011.02.016","volume":"50","author":"G Heusch","year":"2011","unstructured":"Heusch G, Skyschally A, Schulz R (2011) The in-situ pig heart with regional ischemia\/reperfusion - ready for translation. J Mol Cell Cardiol 50:951\u2013963. \nhttps:\/\/doi.org\/10.1016\/j.yjmcc.2011.02.016","journal-title":"J Mol Cell Cardiol"},{"key":"733_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/01.CIR.71.5.1029","volume":"71","author":"GR Heyndrickx","year":"1985","unstructured":"Heyndrickx GR, Amano J, Patrick TA, Manders WT, Rogers GG, Rosendorff C, Vatner SF (1985) Effects of coronary artery reperfusion on regional myocardial blood flow and function in conscious baboons. Circulation 71:1029\u20131037","journal-title":"Circulation"},{"key":"733_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","volume":"18","author":"S Kawasoe","year":"2017","unstructured":"Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, Kubozono T, Ohishi M (2017) Mechanism of the blood pressure-lowering effect of sodium\u2013glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol 18:23. \nhttps:\/\/doi.org\/10.1186\/s40360-017-0125-x","journal-title":"BMC Pharmacol Toxicol"},{"key":"733_CR26","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1161\/01.CIR.102.16.1977","volume":"102","author":"HH Klein","year":"2000","unstructured":"Klein HH, Pich S, Bohle RM, Lindert-Heimberg S, Nebendahl K (2000) Na(+)\/H(+) exchange inhibitor cariporide attenuates cell injury predominantly during ischemia and not at onset of reperfusion in porcine hearts with low residual blood flow. Circulation 102:1977\u20131982","journal-title":"Circulation"},{"key":"733_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/bf03091772","volume":"18","author":"LJ Klein","year":"2010","unstructured":"Klein LJ, Visser FC (2010) The effect of insulin on the heart: Part 2: effects on function during and post myocardial ischaemia. Neth Heart J 18:255\u2013259. \nhttps:\/\/doi.org\/10.1007\/bf03091772","journal-title":"Neth Heart J"},{"key":"733_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.10.002","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM (2019) SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci. \nhttps:\/\/doi.org\/10.1016\/j.jacbts.2018.10.002","journal-title":"JACC Basic Transl Sci"},{"key":"733_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/978-94-007-2888-2_52","volume":"740","author":"Q Lou","year":"2012","unstructured":"Lou Q, Janardhan A, Efimov IR (2012) Remodeling of calcium handling in human heart failure. Adv Exp Med Biol 740:1145\u20131174. \nhttps:\/\/doi.org\/10.1007\/978-94-007-2888-2_52","journal-title":"Adv Exp Med Biol"},{"key":"733_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR, Group CPC (2018) Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). Circulation 137:323\u2013334. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038","journal-title":"Circulation"},{"key":"733_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","volume":"19","author":"P Martens","year":"2017","unstructured":"Martens P, Mathieu C, Verbrugge FH (2017) Promise of SGLT2 inhibitors in heart failure: diabetes and beyond. Curr Treat Options Cardiovasc Med 19:23. \nhttps:\/\/doi.org\/10.1007\/s11936-017-0522-x","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"733_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1161\/res.90.1.11","volume":"90","author":"RL Moss","year":"2002","unstructured":"Moss RL, Fitzsimons DP (2002) Frank\u2013Starling relationship: long on importance, short on mechanism. Circ Res 90:11\u201313. \nhttps:\/\/doi.org\/10.1161\/res.90.1.11","journal-title":"Circ Res"},{"key":"733_CR33","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2337\/dc16-0542","volume":"39","author":"S Mudaliar","year":"2016","unstructured":"Mudaliar S, Alloju S, Henry RR (2016) Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis. Diabetes Care 39:1115\u20131122. \nhttps:\/\/doi.org\/10.2337\/dc16-0542","journal-title":"Diabetes Care"},{"key":"733_CR34","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.2337\/dc15-0642","volume":"38","author":"S Mudaliar","year":"2015","unstructured":"Mudaliar S, Polidori D, Zambrowicz B, Henry RR (2015) Sodium\u2013glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38:2344\u20132353. \nhttps:\/\/doi.org\/10.2337\/dc15-0642","journal-title":"Diabetes Care"},{"key":"733_CR35","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:2099. \nhttps:\/\/doi.org\/10.1056\/NEJMc1712572","journal-title":"N Engl J Med"},{"key":"733_CR36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/iub.1323","volume":"66","author":"A Odunewu-Aderibigbe","year":"2014","unstructured":"Odunewu-Aderibigbe A, Fliegel L (2014) The Na(+)\/H(+) exchanger and pH regulation in the heart. IUBMB Life 66:679\u2013685. \nhttps:\/\/doi.org\/10.1002\/iub.1323","journal-title":"IUBMB Life"},{"key":"733_CR37","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1161\/01.res.88.4.376","volume":"88","author":"NG Perez","year":"2001","unstructured":"Perez NG, de Hurtado MC, Cingolani HE (2001) Reverse mode of the Na+\u2013Ca2+ exchange after myocardial stretch: underlying mechanism of the slow force response. Circ Res 88:376\u2013382. \nhttps:\/\/doi.org\/10.1161\/01.res.88.4.376","journal-title":"Circ Res"},{"key":"733_CR38","doi-asserted-by":"publisher","first-page":"H2260","DOI":"10.1152\/ajpheart.01153.2004","volume":"288","author":"HK Saini","year":"2005","unstructured":"Saini HK, Dhalla NS (2005) Defective calcium handling in cardiomyocytes isolated from hearts subjected to ischemia-reperfusion. Am J Physiol Heart Circ Physiol 288:H2260\u20132270. \nhttps:\/\/doi.org\/10.1152\/ajpheart.01153.2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"733_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-018-06850-0","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Garcia-Ropero A, Mancini D, Pinney SP, Contreras JP, Fergus I, Abascal V, Moreno P, Atallah-Lajam F, Tamler R, Lala A, Sanz J, Fuster V, Badimon JJ (2019) Rationale and design of the EMPA-TROPISM Trial (ATRU-4): are the \"Cardiac Benefits\" of empagliflozin independent of its hypoglycemic activity? Cardiovasc Drugs Ther. \nhttps:\/\/doi.org\/10.1007\/s10557-018-06850-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"733_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0033-0620(88)90011-4","volume":"31","author":"W Schaper","year":"1988","unstructured":"Schaper W, Gorge G, Winkler B, Schaper J (1988) The collateral circulation of the heart. Prog Cardiovasc Dis 31:57\u201377","journal-title":"Prog Cardiovasc Dis"},{"key":"733_CR41","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1517\/17425255.2014.873788","volume":"10","author":"AJ Scheen","year":"2014","unstructured":"Scheen AJ (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol 10:647\u2013663. \nhttps:\/\/doi.org\/10.1517\/17425255.2014.873788","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"733_CR42","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.amjmed.2017.04.009","volume":"130","author":"B Staels","year":"2017","unstructured":"Staels B (2017) Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Med 130:S30\u2013S39. \nhttps:\/\/doi.org\/10.1016\/j.amjmed.2017.04.009","journal-title":"Am J Med"},{"key":"733_CR43","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","volume":"85","author":"WC Stanley","year":"2005","unstructured":"Stanley WC, Recchia FA, Lopaschuk GD (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85:1093\u20131129. \nhttps:\/\/doi.org\/10.1152\/physrev.00006.2004","journal-title":"Physiol Rev"},{"key":"733_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, Jancev M, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61:722\u2013726. \nhttps:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"key":"733_CR45","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1161\/01.RES.0000125626.33738.E2","volume":"94","author":"XH Wehrens","year":"2004","unstructured":"Wehrens XH, Lehnart SE, Reiken SR, Marks AR (2004) Ca2+\/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94:e61\u201370. \nhttps:\/\/doi.org\/10.1161\/01.RES.0000125626.33738.E2","journal-title":"Circ Res"},{"key":"733_CR46","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117\u20132128. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-019-0733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00395-019-0733-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-019-0733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:12:08Z","timestamp":1573643528000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00395-019-0733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["733"],"URL":"https:\/\/doi.org\/10.1007\/s00395-019-0733-2","relation":{},"ISSN":["0300-8428","1435-1803"],"issn-type":[{"value":"0300-8428","type":"print"},{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,19]]},"assertion":[{"value":"9 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflicts of interest to disclose for AK, KM, JD, SL, BS, CE, and AG. HB is a full-time graduate student at Indiana University and an employee of Eli Lilly and Co., but received no compensation from Eli Lilly for the work performed in this study. AR and WR are both employees of Eli Lilly and Co.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"25"}}